• Smoore published its annual report for year ended Dec. 31, 2025, highlighting record revenue driven by growth in vaping devices and first scalable heat-not-burn shipments.
• Heat-not-burn business scaled with a strategic customer’s premium product launches across Japan, Poland, Italy, generating more than RMB 1.2 billion in revenue.
• Electronic vaping operations expanded across both corporate-client and self-branded channels, supported by faster rollout of compliant product designs in Europe and a return to growth in US corporate-client demand.
• Inhalation therapy unit Transpire Bio advanced multiple drug-device combination programs, securing an FDA Establishment Inspection Report for its Florida manufacturing site following a pre-approval inspection.
• Board proposed a final dividend of HKD 0.2 per share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Smoore International Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260416-12108236), on April 16, 2026, and is solely responsible for the information contained therein.